Title: Pazopanib, a Receptor Tyrosine Kinase Inhibitor, Suppresses Tumor Growth through Angiogenesis in Dedifferentiated Liposarcoma Xenograft Models
Authors: Li, Haifu
Wozniak, Agnieszka
Sciot, Raf
Cornillie, Jasmien
Wellens, Jasmien
Van Looy, Thomas
Vanleeuw, Ulla
Stas, Marguerite
Hompes, Daphne
Debiec-Rychter, Maria
Schöffski, Patrick # ×
Issue Date: Dec-2014
Publisher: Neoplasia Press
Series Title: Translational Oncology vol:7 issue:6 pages:665-71
Article number: 10.1016/j.tranon.2014.09.007
Abstract: The rarity of dedifferentiated liposarcoma (DDLPS) and the lack of experimental DDLPS models limit the development of novel therapeutic strategies. Pazopanib (PAZ) is a tyrosine kinase inhibitor that is approved for the treatment of non-adipocytic advanced soft tissue sarcoma. The activity of this agent has not yet been properly explored in preclinical liposarcoma models nor in a randomized phase Ш clinical trial in this entity. The aim of the present study was to investigate whether PAZ had antitumor activity in DDLPS models in vivo.
ISSN: 1944-7124
Publication status: published
KU Leuven publication type: IT
Appears in Collections:Department of Human Genetics - miscellaneous
Laboratory of Experimental Oncology
Translational Cell & Tissue Research
Surgical Oncology
Laboratory for Genetics of Malignant Disorders
× corresponding author
# (joint) last author

Files in This Item:
File Description Status SizeFormat
Li Translational Oncology.pdfpublisher's version pdf Published 781KbAdobe PDFView/Open Request a copy

These files are only available to some KU Leuven Association staff members


All items in Lirias are protected by copyright, with all rights reserved.

© Web of science